Hofseth BioCare ASA Approves Prospectus for Private Placement Shares
News related to:Hofseth BioCare ASA · 2 min read
Hofseth BioCare ASA, a Norwegian consumer and pet health company, has taken a significant step in its growth strategy by successfully completing a private placement of new shares. On 28 June 2026, the company issued 111,154,608 new Ordinary Shares, each priced at NOK 1.30, raising gross proceeds of approximately NOK 144.5 million. This private placement was divided into two tranches: the first tranche, comprising 78,334,609 Offer Shares, was issued pursuant to a Board authorization. The second tranche, consisting of 32,819,999 Offer Shares, was issued by an extraordinary general meeting of the company held on 30 July 2026. These shares were initially delivered on a non-tradable ISIN, pending the approval and publication of a listing prospectus.
On 9 October 2024, the Financial Supervisory Authority of Norway approved the Prospectus. This document is now available on the company’s website at www.hofsethbiocare.com. Following the publication of the Prospectus, the 32,819,999 Listing Shares will be transferred to the ordinary ISIN of the company’s Ordinary Shares and will be admitted to trading on Euronext Oslo Børs.
Hofseth BioCare ASA, founded on the principles of sustainability, optimal utilization of natural resources, and full traceability, upcycles side streams from the salmon industry. The company’s products, ProGo®, OmeGo®, and CalGo®/NT-II®, are designed to improve human and pet health. These ingredients are derived from fresh filleted salmon, transforming waste into valuable health products. The company places a strong emphasis on scientific evidence, leading to important academic partnerships and the identification of unique health benefits. Currently, Hofseth BioCare ASA is listed on the Oslo Stock Exchange with the ticker "HBC."
Advokatfirmaet CLP DA is acting as the legal adviser to the company throughout this process.
The approval of the Prospectus by the Financial Supervisory Authority of Norway is a critical step in the company’s journey to become a publicly traded entity. This move will enable the company to access a broader investor base and enhance its visibility in the market. The company is committed to maintaining its focus on sustainability and innovation, ensuring that its products continue to deliver health benefits while contributing to a more sustainable future.
The approval of the Prospectus and the subsequent listing on Euronext Oslo Børs will provide Hofseth BioCare ASA with the necessary platform to achieve its strategic objectives and further its mission of improving health through the use of natural resources.